Justice GCC
ar ع
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
Reading: UAE First Worldwide to Conditionally Approve Ultomiris for Primary IgA Nephropathy
Share
Justice GCCJustice GCC
Font ResizerAa
  • Legislation
  • Courts
  • Law Firms
  • Deals
Search
  • Home
  • Legislation
  • Courts
  • Law Firms
  • Deals
  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC > Legislation > UAE First Worldwide to Conditionally Approve Ultomiris for Primary IgA Nephropathy
Legislation

UAE First Worldwide to Conditionally Approve Ultomiris for Primary IgA Nephropathy

NewsDesk
Last updated: November 10, 2026 6:55 pm
NewsDesk
Share
UAE First Conditionally Approves Ultomiris for IgA Nephropathy | AI-Generated Image
SHARE

The Emirates Drug Establishment granted conditional approval for a new use of AstraZeneca’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who face a high risk of disease progression. This decision positions the UAE as the first nation globally to authorise the indication for the complement inhibitor, which is administered intravenously. The Emirates Drug Establishment emphasised that the approval followed a rigorous scientific assessment balancing innovation with standards of safety, quality and efficacy. Primary IgA nephropathy, an immune-mediated condition, results from the deposition of immunoglobulin A in kidney tissue, triggering inflammation that can lead to a progressive loss of function.

A review of global incidence data published in Nephrology Dialysis Transplantation places the adult rate of IgA nephropathy at roughly 2.5 cases per 100,000 people annually. Studies of glomerular disease patterns across Arab countries, compiled in a systematic review, show the condition accounts for between 4 and 8 percent of primary glomerular disease cases. Elevated protein levels in urine serve as a critical marker of progression, and treatments that lower proteinuria can slow the decline toward kidney failure. Up to half of patients may reach end-stage kidney disease within 10 to 20 years without effective intervention. A recent meta-analysis of more than 15,000 patients found that even low-grade proteinuria between 0.5 and 1.0 grams per day raises the risk of adverse kidney outcomes by 73 percent compared with levels below 0.5 grams.

The conditional approval expands Ultomiris indications in the UAE, where the medicine has carried registration since 2022 for treating several rare diseases. The Emirates Drug Establishment noted that the move aligns with national priorities under the We the UAE 2031 vision to advance healthcare innovation and pharmaceutical leadership. Officials highlighted the need for early diagnosis together with regular monitoring of kidney function and urinary protein levels. Patients should adhere strictly to regimens prescribed by specialist physicians to manage the condition and minimise complications.

Dr Ruqaya Aqeel Al Bastaki, acting executive director of the medical products regulation sector at the Emirates Drug Establishment, described the regulatory framework as one that keeps pace with pharmaceutical advances while upholding the highest standards. The official added that the approval demonstrates the effectiveness of this balanced approach in accelerating access to new therapies. Her comments came in the announcement detailing the scientific basis for the decision.

Sameh El Fangary, Gulf Cluster president at AstraZeneca, characterised the conditional approval as an important step toward broadening treatment options for eligible patients in the UAE. The executive said his company looks forward to ongoing collaboration with local partners to improve access, treatment outcomes and overall quality of care. AstraZeneca developed ravulizumab, marketed as Ultomiris, as a long-acting C5 complement inhibitor that has established use across multiple rare conditions.

The development arrives as global health authorities, including the US Food and Drug Administration, have also moved toward approvals for complement inhibitors in IgA nephropathy based on proteinuria reduction data. Industry assessments indicate that such therapies address a significant unmet need in a disease that remains the most common form of primary glomerulonephritis worldwide. The Emirates Drug Establishment continues to evaluate emerging treatments to strengthen the country’s position in pharmaceutical regulation and patient care.

Share This Article
Email Copy Link Print
ByNewsDesk
Justice GCC NewsDesk is the desk responsible for Justice GCC's daily news coverage, monitoring and reporting developments across the Gulf from official sources, including national news agencies and government communications. Its focus is accurate, timely and factual coverage of the region.
Previous Article Capmont Acquires Majority Stake in Germany’s Kramer Group in Founder Succession Deal
Next Article UAE Sets E-Scooter Permit Rules and Nine-Hour Driving Limit Ahead of 2027 Rollout

Popular Posts

Saudi Court Sentences Kenyan Migrant Worker to 100 Lashes for Extramarital Birth

A Saudi court sentenced Kenyan domestic worker Esther Wanja Muthoni to 100 lashes after she gave birth outside marriage in…

By
NewsDesk
3 Min Read
Emirates Drug Establishment First to Approve Ultomiris for Proteinuria in IgA Nephropathy

The Emirates Drug Establishment granted conditional approval on November 10, 2026 for…

5 Min Read
Baker McKenzie Recruits Data Protection Expert Kelly Hagedorn in London Lateral Move

Baker McKenzie announced the appointment of Kelly Hagedorn as a cybersecurity and…

3 Min Read

More News

Qatar Denounces Iranian Strikes on Kuwait and Bahrain as Breaches of Sovereignty

Qatar's Ministry of Foreign Affairs condemned renewed Iranian attacks on…

November 18, 2026

VAT Group Closes Atonarp Acquisition Financed by CHF 110 Million Bilateral Loan

VAT Group completed the acquisition of…

November 18, 2026

Natroshvili Expands Business Portfolio With UAE Legal Advisory Launch

David Natroshvili, ranked the most influential…

November 17, 2026

Iran Condemns Bahrain’s Life Sentences for Shia Clerics as Rights Abuse

Iran's Foreign Ministry on November 17,…

November 17, 2026

Bahraini Court Sentences 64 to Life in Prison Over Alleged Iran Links

A Bahraini court on November 16…

November 17, 2026

Recommended for You

Legislation

Bitcoin Crosses $80,000 for First Time Since May on Policy Support

Bitcoin surged above $80,000 on August 25, 2026 for the first time since mid-May as Treasury bond buybacks weakened the…

4 Min Read
Legislation

Kuwait Recalls Legislative Reforms and Diplomatic Ties in Annual Historical Review

Kuwait Times on October 7, 2026 highlighted several landmark events from the nation's past that occurred on this date, ranging…

3 Min Read
Legislation

Saudi Authority Issues Guide Cataloguing Over 100 Types of AI Bias

The Saudi Data and Artificial Intelligence Authority released its first AI Bias Reference Guide on July 21 2026 identifying more…

4 Min Read
Legislation

Dhofar Forum Highlights AI and Employment as Key to Disability Inclusion in Oman

A two-day forum on independent living for persons with disabilities opened in Salalah on Wednesday with artificial intelligence and employment…

3 Min Read

Categories

  • Legislation
  • Courts
  • Law Firms
  • Deals

Quick Links

  • About
  • Corrections
  • Editorial Policy
  • Contact
Justice GCC
© 2026 Justice GCC. Published by Peninsula News Group LLC. All rights reserved.
  • Privacy Policy
  • Terms of Use
  • Contact
Welcome to Foxiz

Sign in to your account

Username or Email Address
Password

Lost your password?